Literature DB >> 19139205

Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment.

J M Meijer, J Pijpe, A Vissink, C G M Kallenberg, H Bootsma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19139205     DOI： 10.1136/ard.2008.092601

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  13 in total

Review 1.  Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.

Authors:  A Vossenkämper; P M K Lutalo; J Spencer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 2.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

3.  Preclinical validation of salivary biomarkers for primary Sjögren's syndrome.

Authors:  Shen Hu; Kai Gao; Rodney Pollard; Martha Arellano-Garcia; Hui Zhou; Lei Zhang; David Elashoff; Cees G M Kallenberg; Arjan Vissink; David T Wong
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07-08       Impact factor: 4.794

Review 4.  [Current therapeutic options in Sjögren's syndrome].

Authors:  A Hansen; T Dörner
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

Review 5.  Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.

Authors:  M J Leandro; I de la Torre
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 6.  [Diagnostic and therapy of salivary gland diseases: relevant aspects for the pathologist from the clinical perspective].

Authors:  C Wittekindt; H P Burmeister; O Guntinas-Lichius
Journal:  Pathologe       Date:  2009-11       Impact factor: 1.011

7.  Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice.

Authors:  Jason S Ellis; Xiaoxiao Wan; Helen Braley-Mullen
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

Review 8.  The value of animal models to study immunopathology of primary human Sjögren's syndrome symptoms.

Authors:  Amy Donate; Alexandria Voigt; Cuong Q Nguyen
Journal:  Expert Rev Clin Immunol       Date:  2014-02-10       Impact factor: 4.473

Review 9.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 10.  Sjögren's syndrome in older patients: aetiology, diagnosis and management.

Authors:  Rada V Moerman; Hendrika Bootsma; Frans G M Kroese; Arjan Vissink
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.